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Abstract
Background
Parkinson’s disease (PD) is a debilitating illness associated with considerable impairment
of quality of life and substantial costs to health care systems. Deep brain stimulation (DBS)
is an established surgical treatment option for some patients with advanced PD. The EAR-
LYSTIM trial has recently demonstrated its clinical benefit also in patients with early motor
complications. We sought to evaluate the cost-effectiveness of DBS, compared to best
medical therapy (BMT), among PD patients with early onset of motor complications, from a
United Kingdom (UK) payer perspective.
Methods
We developed a Markov model to represent the progression of PD as rated using the Uni-
fied Parkinson's Disease Rating Scale (UPDRS) over time in patients with early PD. Evi-
dence sources were a systematic review of clinical evidence; data from the EARLYSTIM
study; and a UK Clinical Practice Research Datalink (CPRD) dataset including DBS
patients. A mapping algorithm was developed to generate utility values based on UPDRS
data for each intervention. The cost-effectiveness was expressed as the incremental cost
per quality-adjusted life-year (QALY). One-way and probabilistic sensitivity analyses were
undertaken to explore the effect of parameter uncertainty.
Results
Over a 15-year time horizon, DBS was predicted to lead to additional mean cost per patient
of £26,799 compared with BMT (£73,077/patient versus £46,278/patient) and an additional
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mean 1.35 QALYs (6.69 QALYs versus 5.35 QALYs), resulting in an incremental cost-effec-
tiveness ratio of £19,887 per QALY gained with a 99% probability of DBS being cost-effec-
tive at a threshold of £30,000/QALY. One-way sensitivity analyses suggested that the
results were not significantly impacted by plausible changes in the input parameter values.
Conclusion
These results indicate that DBS is a cost-effective intervention in PD patients with early
motor complications when compared with existing interventions, offering additional health
benefits at acceptable incremental cost. This supports the extended use of DBS among
patients with early onset of motor complications.
Introduction
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder involving dopa-
minergic neurons, which results in a lack of the neurotransmitter dopamine. Clinically the hall-
mark of PD is a movement disorder with bradykinesia, rigidity and often rest tremor, although
non-motor signs and symptoms are also common [1,2]. A recent-meta-analysis concluded that
the worldwide prevalence of PD is around 315 cases per 100,000 population [3]. During early
stages of the disease, patients are effectively treated with oral medication such as levodopa;
however, over time, medication-induced motor complications such as unpredictable fluctua-
tions in motor symptoms and abnormal involuntary movements (dyskinesias) develop [4].
Progressively, the disease leads to increasingly severe motor signs, worsening of medication-
related complications and a decrease in the time between ‘off’ periods when symptoms are not
well-controlled. In advanced stages axial motor signs such as impaired balance and gait that
respond less favourably to levodopa or DBS become more prevalent and non-motor, especially
psychiatric and cognitive problems cause significant loss of quality of life [4–8]. Thus, there is a
time window between the occurrence of levodopa-induced motor complications and the devel-
opment of levodopa-resistant symptoms of PD when DBS can potentially improve the patients’
condition.
PD imposes a significant burden upon patients’ health-related quality of life [9–15], and cre-
ates a major economic burden for health care systems, driven mainly by hospitalisations and
medication [9,16–20]. A broader socio-economic impact also occurs due to lost income owing
to a reduced capacity to work, early retirement and institutional or unpaid care provided by
patients’ relatives [17,18,21–27]. One European study has shown that a one-unit increase on
the dyskinesia severity scale (Part IVa of the Unified Parkinson’s Disease Rating Scale
(UPDRS)) results in additional mean combined medical and non-medical cost of €737 per
patient over a 6-month period [21]. When indirect costs are included, this cost increases three-
fold [27]. For patients who in principle respond well to dopaminergic medication but whose
benefit from oral medication is hampered by motor complications (fluctuations and dyskine-
sia), treatment options include deep brain stimulation (DBS), a surgical treatment which
involves the implantation of a device for electrical stimulation of precise areas in the brain.
Modulation of the activity of specific target structures in the brain results in improvement of
certain parkinsonian motor signs. Current guidelines in the United Kingdom (UK) from the
National Institute for Health and Care Excellence (NICE) recommend the use of DBS. These
guidelines are currently being updated and will consider all relevant interventions including
DBS [28].
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Randomised controlled trial (level I) evidence support the use of DBS in advanced PD [29–
31]. Previous economic studies have concluded that DBS is a cost-effective intervention, when
compared with best medical therapy (BMT) among patients with advanced PD [32–35]. Fur-
thermore, recent clinical evidence (the EARLYSTIM trial) has demonstrated that DBS is also
effective in PD patients earlier in the disease course, with recent onset motor complications
[36,37]. Significant improvements were observed compared with BMT in motor disability,
activities of daily living, levodopa-induced motor complications and time with good mobility
[36].
This study sought to assess the cost effectiveness of DBS versus BMT in treating PD from
early onset of motor complications from a UK payer (National Health Service) perspective,
employing a novel approach of associating UPDRS subscales with health-related quality of life
to capture the multi-faceted aspects of PD.
Materials and Methods
This economic modelling study was undertaken and reported in accord with the International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) best practice modelling
guidelines [38].
Overview of the economic model
We developed a Markov (state-transition) model to calculate the costs and health outcomes (in
terms of life-years and quality-adjusted life-years [QALYs]) associated with a range of inter-
ventions for PD patients. Specifically, the model considered two treatment options:
• BMT: BMT alone
• DBS: DBS in combination with BMT.
Baseline characteristics for patients for both treatment options were based upon data from
the EARLYSTIM study [36], i.e. all patients were assumed to have PD with early motor compli-
cations at model entry (i.e. those with motor fluctuations or dyskinesias present for 3 years or
less). The model was developed in Microsoft Excel (Microsoft Corporation, Redmond, MA,
USA), and in the base-case analysis a 15-year horizon was used to capture long-term results
and progression to more advanced disease stages. A lifetime horizon in the base-case analyses
was not considered appropriate given the uncertainty in long-term outcomes for patients on
the therapies evaluated. A one-year cycle length was used for transitions between health states,
and a half-cycle correction was applied to reflect the fact that patients move between states, on
average, halfway through a cycle [39]. Health states were based around treatment interventions
(see Fig 1), and for each treatment, disease progression was modelled according to changes in
the UPDRS domain scores (Parts I to IV). The changes in UPDRS domain scores were
recorded over time within the model, but were not explicitly used to derive health states.
Health-related quality of life was accounted for using an existing mapping algorithm (in the
short-term), and via the development of a new algorithm to link UPDRS scores to the Euroqol-
5D (EQ-5D) in the long-term (see below). Costs and QALYs were both discounted at 3.5% per
year, according to NICE methods guidance [40]. A systematic literature review was undertaken
to identify relevant clinical data for each intervention; unit cost data were sourced from device
price lists, national drug prices, hospital payment tariffs and social care cost data. Input was
sought from a panel of clinical experts (PE, AG, AW, MS, AW) to ensure appropriate use of
the data and for validation of the model structure and assumptions. A full table of input param-
eter values can be found in the Supplementary Information (S1 Table).
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Model structure and treatment comparisons
Fig 1 shows the model structure and health states for each intervention.
DBS patients would continue therapy until withdrawal, after which they would continue
with BMT until the end of the model horizon or until death. No further interventions were
modelled for patients withdrawing from DBS.
Clinical data
A systematic literature review (including searches of PubMed, Embase, and The Cochrane
Library) was undertaken to identify relevant short- and long-term clinical outcomes data for
PD patients, and for each of interventions considered in the analysis. The systematic review
considered studies among adult patients with PD which reported mean UPDRS scores at speci-
fied time points in the ‘ON’ state (i.e. on medication) (details of the systematic review are avail-
able in the supplementary information).
Disease progression and treatment effectiveness were modelled in terms of changes in
UPDRS scores (Parts I to IV) over time for each intervention. Baseline characteristics of
patients (in terms of mean UPDRS scores on each domain, and with a mean age of 52 years) in
the model were based on pooled data from the DBS and BMT treatment groups of the EAR-
LYSTIM study [36]. In the DBS and BMT treatment groups of the EARLYSTIM study, UPDRS
domain scores were collected at treatment initiation and at 5, 12 and 24 months, which were
used to calculate the percentage change from baseline in each domain score.
Disease progression beyond two years was modelled in a uniform way across all treatments,
due to a lack of consistent long-term data on UPDRS outcomes for each intervention. Each
UPDRS domain was modelled using data pooled from various studies, since no studies
reported all domains consistently. Data from studies with a BMT treatment group were used to
model the annual progression rate of UPDRS Parts I, II and IV [5,36,41–44]; a long-term study
of DBS was used to represent progression of UPDRS III [45]. These rates were applied to both
treatment options after two years, with the exception of UPDRS Part IV score. Clinical evi-
dence suggests that UPDRS Part IV improvements may be more long-term for DBS patients
[45–52]; in particular, two studies have demonstrated UPDRS IV scores at 8 years which are
significantly better than baseline scores and not significantly different from corresponding
scores at one year [50,51]. On the basis of this evidence, the clinical expert panel advised an
extension of DBS response for this outcome; thus, the model held the two-year Part IV score
constant for a further eight years, after which progression occurred at the same rate as for
Fig 1. Model diagramBMT = best medical therapy; DBS = Deep brain stimulation.
doi:10.1371/journal.pone.0159340.g001
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BMT. Alternative assumptions regarding the long-term effect of DBS upon UPDRS IV scores
were tested in sensitivity analyses.
Mortality data
Mortality was incorporated using a two-step approach. Firstly, an age- and gender-specific
baseline mortality risk was applied using UK all-cause mortality rates [53], with patients enter-
ing the model at age 52.5 years, based on the EARLYSTIM study [36]. Whilst evidence suggests
that in the early stages of PD, mortality is not significantly different to that of the general popu-
lation [54–56], a recent review of mortality data in PD indicated that patients with advanced
disease have a higher mortality risk [57]. Using data from studies reporting the relationship
between UPDRS Part III and mortality, a 10-point increase in the UPDRS Part III score was
associated with an increased mortality risk by applying a hazard ratio of 1.31 to the baseline
risk [58,59,60]. This increased risk was applied to patients with a UPDRS Part III score of 15 or
more, to reflect the impact only amongst patients with advanced disease.
Adverse events
The model accounted for both treatment-specific and disease-related adverse events (AEs).
Three AE types among DBS patients were included, i.e. surgery-related AEs (such as bleeding
events and infections); hardware-related AEs (e.g. lead fractures and migrations); and other
AEs such as worsening of mobility. Serious adverse event data from the EARLYSTIM study
were used to inform the frequency of each event type [36]. Surgery-related AEs were modelled
to only occur in the first two years following implantation; hardware-related and other AEs
were associated with an ongoing risk. For BMT, EARLYSTIM study data were again used to
model incidence of serious AEs, including worsening of mobility and motor fluctuations [36].
These risks were assumed to be constant over time.
PD progression is associated with increasing postural instability, leading to falls and in
some cases serious injury to patients. To reflect the risk of falling, we pooled data from a series
of studies to define the baseline proportion of patients falling per year as 42.78% [61–75]. An
odds ratio of 1.07 for each point increase in UPDRS III score was then applied, derived from
three studies of fall incidence [61,64,66]. Of these falls, 50.9% were assumed to require hospita-
lisation of the patient [62,65,72]. The clinical panel suggested that withdrawal from DBS is
rare; therefore, we modelled DBS withdrawal only as a consequence of specific adverse events.
Withdrawal probabilities in the other treatment groups were calculated based on studies
reporting such data. Upon withdrawal from DBS patients were assumed to receive BMT until
death or the end of the model horizon, with UPDRS scores reflecting this change of treatment.
Quality of life data
UK guidelines for economic evaluations state that health outcomes should be expressed in
terms of QALYs, with the EuroQol-5D (EQ-5D) being the preferred measure of health-related
quality of life [40]. EQ-5D data were not collected in the EARLYSTIM study, and we therefore
used a published algorithm to map from the 39-item Parkinson’s Disease Questionnaire
(PDQ-39) data from EARLYSTIM to the EQ-5D [76]. The algorithm used a multinomial logis-
tic regression approach to predict the spread of patients between the three levels of each of the
five domains of the EQ-5D. These values were then used to derive a utility index for a UK pop-
ulation [77], with a utility weight calculated for DBS and BMT patients separately by averaging
across the data from months 5 and 12 (for the year 1 utility) and months 12 and 24 (for the
year 2 utility) in the EARLYSTIM study. These utility weights were applied in the first two
years of the model.
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Whilst studies have demonstrated a correlation between UPDRS Parts I and II and both the
EQ-5D index and the PDQ-39 [78,79], existing algorithms do not fully capture this relation-
ship [80]. For this reason we developed a new algorithm to apply after the first two years of the
model for both treatment groups. An iterative process was used to identify a statistical model
which could accurately predict the EQ-5D index from the explanatory variables available from
the EARLYSTIM study (including UPDRS domain scores, and patient gender and age). Several
model types were explored, including linear regression, beta regression, and finite mixtures of
linear and beta regression with a range of link functions. A comparison of model fit was made
using mean error, mean absolute error, the Bayesian information criterion and the Akaike
information criterion. A beta regression approach with a log link function was considered the
most appropriate, as it resulted in small errors, covered the full range of utility values possible
with the EQ-5D and did not produce illogical results (e.g. worse UPDRS scores leading to
higher utilities). The function is given below:
EQ 5D ¼ 1:59  eð0:01721Maleþ0:001448Age0:0198UPDRS I0:00049ðUPDRS IIÞ20:0178UPDRS IV0:2468Þ  0:594
Where ‘Male’ is set to one for males and zero for females.
The algorithm was subsequently applied to patients’ changing UPDRS scores over time in
the model to predict variation in health-related quality of life for the remainder of the model.
Cost and resource use data
The cost analysis was undertaken from a UK National Health Service perspective. The main
cost groups included were: pre-surgery hospitalisation; device acquisition and implantation;
drug acquisition (BMT); adverse event management (treatment-specific and generic events);
general follow-up; treatment withdrawal; and device replacements. Hospital-related costs were
based upon Payment by Results tariffs [81], drug costs were taken from the British National
Formulary [82], and GP and nurse follow-up visits were taken from the Personal Social Sci-
ences Research Unit [83].
For DBS, two pre-operative assessments were required to undertake tests on the patient and
prepare them for the implantation procedure. A separate hospitalisation was then included at
which the device, leads and extensions were implanted, with the costs of the full DBS system
applied at this point (i.e. device, leads, extensions and patient programmer) [84]. The cost of a
battery replacement was assumed to include the cost of a new device, plus a hospitalisation for
the procedure, with a mean battery lifetime of 4.5 years used [85]. The costs of AE management
were based on the frequency of serious AEs observed in the EARLYSTIM trial, with separate
costs applied to surgery-related events, device-related events and other events observed in the
study [81,86]. In some cases, more than one plausible payment tariff was identified, and in
such instances the mean of the available tariffs was applied.
Given the range of drug options available for PD management and the lack of standardised
drug protocols, we calculated drug use across treatment options for BMT using an analysis of
data from the UK Clinical Practice Research Datalink (CPRD) [87]. Data were extracted on a
total of 297 patients (270 on BMT and 27 on DBS) for the period April 1 2003 to March 31
2012, and included information on a total of 305 different PD drug formulations administered
during this period. Dosing information for each patient was combined with drug unit costs
from the British National Formulary [82], and the number of patients receiving each drug
(from the CPRD) to calculate mean daily drug costs for each treatment group. The calculated
drug cost per day for each treatment option was £4.16 (BMT) and £2.28 (DBS). These costs
were assumed to be constant over time.
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The costs of general follow-up were accounted for in each treatment group via regular neu-
rology outpatient appointments. For patients receiving DBS, four visits were assumed in the
first year of treatment to account for device programming and drug dose adjustments, with
two visits assumed per year thereafter. Patients on BMT were assumed to require two visits per
year for the duration of the model, except in the case of patients withdrawing from DBS, who
were assumed to require four such visits in the first year after withdrawal. Home visits by a PD
nurse were applied in both treatment groups with the same frequency as for the neurology out-
patient visits.
PD-related falls were assumed to require hospitalisation in 50.9% of cases [62,64,72]. The
unit costs of follow-up and falls were based on national tariffs and social service cost estimates
[81,83]. Finally, the costs of any additional hospitalisations were included for each treatment
option. The CPRD dataset of PD patients (364 patients, described above) was used to estimate
the mean number of inpatient days per patient per year [87], which were adjusted for hospitali-
sations related to treatment and adverse events described above, and then multiplied by a cost
per hospital day. The mean number of hospital days per patient was estimated as 5.97 (BMT)
and 2.63 (DBS). According to expert clinical advice, these hospitalisations can be assumed to
be mainly due to PD-related co-morbidities.
A full list of the unit costs used in the model is given in S1 Table in the Supporting Material.
Data Analyses
A deterministic analysis was firstly undertaken, using the mean value of each parameter to cal-
culate the total costs, life-years and QALYs over a 15-year horizon. To allow comparison of the
cost-effectiveness of the two interventions, the incremental cost-effectiveness ratio (ICER) was
calculated using the following formula (‘A’ and ‘B’ refer to the two interventions being com-
pared):
ICER ¼ CostsA  CostsB
QALYsA  QALYsB
To explore the effect of individual parameter uncertainty upon the cost-effectiveness results,
extensive one-way sensitivity analyses were also undertaken, varying each parameter in turn
within plausible ranges. Probabilistic sensitivity analysis (PSA) was performed to explore the
joint effect of the uncertainty in all input parameter values. This involved assigning a statistical
distribution to each parameter to reflect the uncertainty in its mean value. A range of distribu-
tions was used (including normal, beta, gamma and lognormal) according to the parameter
type and any necessary restrictions on possible sampled values. One value was sampled from
each parameter’s distribution and the model results re-calculated using these values; this pro-
cess was repeated 10,000 times to provide a range of costs and QALYs for each intervention.
Results
Deterministic analysis
Table 1 shows the discounted results of the deterministic analysis, based on a 15-year time
horizon.
DBS was predicted to lead to improved QALY outcomes and increased costs compared with
BMT, leading to an ICER of £19,887 per QALY gained. In the DBS group, two-thirds of the
total costs were related to device acquisition, implantation and replacement (see Fig 2).
Figs 3 and 4 show the cumulative costs and QALYs over the 15-year period for each
intervention.
Cost-Effectiveness of Deep Brain Stimulation in the UK
PLOSONE | DOI:10.1371/journal.pone.0159340 July 21, 2016 7 / 18
These results show a steady increase in the total costs and QALYs over time for each inter-
vention. The timing of DBS battery replacements can be seen in Fig 3 at regular intervals.
One-way sensitivity analysis
Fig 5 shows the tornado diagram for the comparison of DBS versus BMT. The variables whose
uncertainty was most influential are shown towards the top of the diagram.
The key parameters identified by the one-way sensitivity analysis were: the model time hori-
zon; the cost of the DBS system; the duration of the effect of DBS upon the UPDRS Part IV
score (when this effect was assumed to last for 2 years, a QALY gain of 1.02 was observed for
DBS patients, compared with 1.35 in the base-case); and the DBS battery longevity. In no sce-
nario, however, was the computed ICER for the comparison of DBS versus BMT in excess of
£30,000 per QALY gained.
Probabilistic sensitivity analysis
The results of the probabilistic sensitivity analysis are shown in Figs 6 and 7, with the total
costs and QALYs of each intervention presented. In Fig 6, each point represents one set of
results generated from the sampled input parameter values for each treatment option. Fig 7 is
the cost-effectiveness acceptability curve (CEAC), showing the probability that each treatment
option is cost-effective across a range of willingness-to-pay thresholds.
The scatter plot in Fig 6 shows that, although BMT is less costly than DBS overall, it gener-
ates fewer QALYs. Each cloud of points shows the considerable variability in the total QALYs
gained for each intervention, reflecting the uncertainty in the long-term disease outcomes and
their impact upon health-related quality of life. At a threshold of £20,000 per QALY gained,
Table 1. Deterministic model results (discounted).
Treatment Mean cost per patient Mean QALYs gained per patient ICER (cost per QALY gained)
BMT £46,278 5.35 -
DBS £73,077 6.69 £19,887
QALY = quality-adjusted life-year; ICER = incremental cost-effectiveness ratio
doi:10.1371/journal.pone.0159340.t001
Fig 2. Cost breakdown by treatment.
doi:10.1371/journal.pone.0159340.g002
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the probability of DBS being the most cost-effective intervention was 51%, rising to 99% at a
£30,000 per QALY threshold (see Fig 7).
Discussion
This analysis was undertaken to determine the cost-effectiveness of DBS versus alternative
treatment options in PD patients from early onset of motor complications on over 15 years,
building on existing cost effectiveness evidence of DBS treatment in patients with more
advanced disease. This analysis suggests that DBS is a cost-effective intervention with an ICER
of £19,887 per QALY gained when compared with BMT and below the UK maximum willing-
ness-to-pay threshold of £30,000 per QALY gained [88].
This is the first analysis using the UPDRS scale to model long-term progression based on a
PD population with early onset of motor complications. It supports the majority of the existing
economic evidence in more advanced populations that DBS is cost-effective compared with
BMT[32–34,89]. The recent analysis of DBS from a Swedish societal perspective showed DBS
to be cost-saving compared to BMT [90]. Two published analyses have looked at DBS in
advanced PD from a UK health service perspective. Eggington et al found acceptable ICERs in
Fig 3. Cumulative discounted costs over 15 years.
doi:10.1371/journal.pone.0159340.g003
Fig 4. Cumulative discounted QALYs over 15 years.
doi:10.1371/journal.pone.0159340.g004
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their modelled analyses using clinical data from the Deuschl RCT [29,33]. In contrast, the anal-
ysis based on the PD SURG study found less favourable results for DBS [89]. The PDSURG-
based analysis used a micro-costing approach to estimate costs related to DBS and BMT, and
its consequences over time. However, given that the clinical study was conducted 10–16 years
ago, some obsolete practices may be reflected. Outdated practices may affect costs and effects,
as patient selection has improved as a result of almost 20 years of experience with DBS, and tar-
geting is more advanced, following the availability of better imaging techniques.
QALY differences between DBS and BMT were very small, non-significant, and possibly
indicative of the disease-specific quality of life benefits (PDQ-39), which were smaller than in
other RCTs (13% in PD SURG versus 24% and 26% in EARLYSTIM and Deuschl (2006),
respectively [29,36,89]. The sensitivity of the PD SURG results to changes in QALYs was dem-
onstrated by one-way sensitivity analyses showing ICERs below willingness-to-pay thresholds
Fig 5. Tornado diagram of one-way sensitivity analysis for DBS versus BMT (plausible parameter
ranges).
doi:10.1371/journal.pone.0159340.g005
Fig 6. Scatter plot of probabilistic results (15-year horizon). The red dot represents the deterministic
result.
doi:10.1371/journal.pone.0159340.g006
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when 30% higher QALY benefits were assumed for DBS. These aspects may explain differences
in cost-effectiveness results between existing studies and the PD SURG analysis.
Our results are in accord with the comparative previous analyses by Dams et al [32] who
find DBS to be highly cost-effective in a sensitivity analysis where they considered an “early”
population. However, this previous analysis used an early PD population at the start of the
model (in terms of the distribution of patients between Hoehn and Yahr stages), applying all
other parameter values as per an advanced PD population.
The modelling approach undertaken here has strengths. We developed an economic model
using UPDRS scores to represent disease progression, and created a mapping algorithm to pro-
vide a link between these scores and patients’ health-related quality of life. The UPDRS-based
model reflects the multi-faceted aspects of Parkinson’s disease, and allowed the use and synthe-
sis of clinical data from multiple studies reporting UPDRS scores as endpoints. We used two-
year data from the EARLYSTIM trial to inform the initial model inputs [36], and supple-
mented this with data identified via a systematic review to project long-term outcomes for each
treatment option. Device costs made up the majority of the costs in the DBS treatment group;
in the BMT group, drug therapy and management of co-morbidities were the main cost driv-
ers. The ICER remained relatively stable when tested in sensitivity analyses; only in a scenario
in which the time horizon was limited to five years was an ICER greater than £30,000 per
QALY gained observed. Uncertainty in long-term outcomes for each treatment was fully
explored and did not lead to substantial changes in the cost-effectiveness results. Probabilistic
sensitivity analysis indicated a high probability of DBS being cost-effective, with much of the
variability in QALY gains due to the uncertainty in long-term disease progression rates and the
long-term relationship between UPDRS scores and quality of life.
We recognise that our analysis has limitations. The time horizon of 15 years was chosen as
the base case in order to capture modelling of long-term health and economic outcomes of a
population with early complications at the start of the model and which develop into more
advanced disease at later model stages. A lifetime horizon was not considered robust enough
given the limitations in the data. The patient data used came from different sources, the longest
of which provided 5 year follow-up information after DBS. Thus, heterogeneity of the data
sources and the lack of actual patient data beyond 5 years are limitations.
Fig 7. Cost-effectiveness acceptability curve.
doi:10.1371/journal.pone.0159340.g007
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As with all health economic modelling exercises, the analysis required a number of assump-
tions to be made, in particular with regard to long-term UPDRS outcomes for different treat-
ments. Wherever assumptions were needed, they were conservative, for example assuming
identical long-term UPDRS progression rates for DBS and BMT patients, with the exception of
UPDRS IV, in which a longer-term benefit for DBS was applied. Further long-term outcomes
data are needed to fully validate these assumptions. The use of a new mapping algorithm to
derive EQ-5D utilities from UPDRS scores also introduced uncertainty, as its applicability to
other datasets has not been evaluated. Nevertheless, the algorithm had high internal validity
and builds on existing algorithms by capturing the relationship between a broader range of
UPDRS domain scores and quality of life.
Alternative therapies are available for the management of PD with motor complications. In
particular, sub-cutaneous apomorphine infusion (CSAI) and continuous duodenal levodopa
carbidopa infusion (CDLCI) have been the focus of studies in patients with advanced PD [91–
103]. However, evidence regarding the efficacy of their use among patients with early motor
symptoms is lacking, and for this reason we excluded these treatment options from this analy-
sis. Existing economic evidence indicates that CDLCI and CSAI are more costly than both DBS
and BMT, [104–106] suggesting that DBS would be a more cost-effective alternative to both of
these treatments. With availability of more robust comparative clinical data, a formal economic
evaluation is needed comparing all treatment options in patients with early complications.
Clinicians are faced with having to make treatment decisions for patients presenting with
motor complications on a continuum of care. In particular, strict inclusion criteria apply for
patients to undergo DBS, and most available data refer to DBS of the subthalamic nucleus.
Many patients in whom this treatment is contraindicated may benefit from CDLCI which is
typically a treatment of advanced and very advanced PD.
In conclusion, we modelled cost-effectiveness of DBS in PD patients with early motor com-
plications over a time horizon of 15 years building on evidence from patients with advanced
disease. Using a novel mapping algorithm to link disease progression with health-related qual-
ity of life, and two-year follow-up data from the EARLYSTIM trial [36], our analysis concludes
that the incremental cost-effectiveness ratio of DBS compared to BMT is acceptable based on
current thresholds. Our findings are line with the evidence for cost-effectiveness of DBS in
advanced PD and provide support from an economical standpoint for the extension of existing
policy recommendations to make DBS available to patients with PD with early motor
complications.
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